Unichem Laboratories Limited manufactures and sells pharmaceutical formulations in India, the United States, Canada, Brazil, and other Latin American markets.
The last earnings update was 322 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Unichem Laboratories. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Unichem Laboratories's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unichem Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Unichem Laboratories's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Unichem Laboratories's earnings growth to the India market average as no estimate data is available.
Unable to compare Unichem Laboratories's revenue growth to the India market average as no estimate data is available.
Unable to determine if Unichem Laboratories is high growth as no earnings estimate data is available.
Unable to determine if Unichem Laboratories is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Unichem Laboratories's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Unichem Laboratories's finances.
The net worth of a company is the difference between its assets and liabilities.
Unichem Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Unichem Laboratories's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Unichem Laboratories's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 15.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Prakash Amrut Mody has been Chairman of the Board and Managing Director of Unichem Laboratories Limited since July 1, 2003. Dr. Mody has a rich experience in the field of marketing, research and production. Dr. Mody has been a Non Executive Independent Director of Kewal Kiran Clothing Limited since November 14, 2005. He serves as a Director of Unichem Laboratories Limited. He serves on the Board of all Subsidiary Companies of Unichem. He serves as the Chairman of the Board of the Industrial pharmacy division of the Indian Pharmaceutical Association. He served as Vice President of the Indian Pharmaceutical Association. He serves as a Member of National committee on drugs and pharmaceuticals of the Confederation of Indian Industry. He serves as on the Executive Committee of the Indian Drug Manufacturers Association. He serves as a Member of the Young President' Organisation Inc., an international organization for young President. He serves as a Member of the Senate - SNDT Women's University and Rotary Club of Bombay Mid-Town and is also involved in many other social activities. Dr. Mody is a doctorate (Ph.D.) in Organic Medicinal Chemistry from the University of Mumbai. He perceived marketing management from Jamnalal Bajaj Institute of Management Studies, University of Mumbai. He is a Graduate Alumni of Harvard Business School having undergone the Owner President' Management Program.
Prakash's compensation has been consistent with company performance over the past year, both up more than 20%.
Prakash's remuneration is about average for companies of similar size in India.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Unichem Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
Chairman & MD
Head of Legal
Director of Technical & Whole-Time Director
Vice President of Human Resources & ER
Head of Projects & Investments
Chief Executive of Domestic Pharma
President of North America & CEO of North America
Vice President of Chemical of Research and Development
Associate Vice President of International Business
Vice President of Commercial
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Unichem Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Something To Consider Before Buying Unichem Laboratories Limited (NSE:UNICHEMLAB) For The 2.6% Dividend
Is Unichem Laboratories Limited (NSE:UNICHEMLAB) a good dividend stock? … Regular readers know we like to apply the same approach to each dividend stock, and we hope you'll find our analysis useful. … While Unichem Laboratories's 2.6% dividend yield is not the highest, we think its lengthy payment history is quite interesting.
Introducing Unichem Laboratories (NSE:UNICHEMLAB), The Stock That Dropped 44% In The Last Year
That downside risk was realized by Unichem Laboratories Limited (NSE:UNICHEMLAB) shareholders over the last year, as the share price declined 44%. … Unichem Laboratories isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Unichem Laboratories grew its revenue by 17% over the last year.
Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?
A look at the shareholders of Unichem Laboratories Limited (NSE:UNICHEMLAB) can tell us which group is most powerful. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Unichem Laboratories is not a large company by global standards.
Why Unichem Laboratories Limited's (NSE:UNICHEMLAB) CEO Pay Matters To You
How Does Prakash Mody's Compensation Compare With Similar Sized Companies. … According to our data, Unichem Laboratories Limited has a market capitalization of ₹13b, and pays its CEO total annual compensation worth ₹14m. … While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at ₹13m
Should You Worry About The Unichem Laboratories Limited's (NSE:UNICHEMLAB) Shareholder Register?
Every investor in Unichem Laboratories Limited (NSE:UNICHEMLAB) should be aware of the most powerful shareholder groups. … Unichem Laboratories is a smaller company with a market capitalization of ₹13.4b, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.
Unichem Laboratories Limited (NSE:UNICHEMLAB): Time For A Financial Health Check
While small-cap stocks, such as Unichem Laboratories Limited (NSE:UNICHEMLAB) with its market cap of ₹16.79b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.
Unichem Laboratories Limited manufactures and sells pharmaceutical formulations in India, the United States, Canada, Brazil, and other Latin American markets. It offers pharma products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients. The company was founded in 1944 and is based in Mumbai, India.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.